00:00Once there is a vaccine that is licensed and approved, COVAX will work to secure at least 220 million doses
00:10of vaccine for the continent.
00:13This will not necessarily cover all the needs of the continent, but at least will cover 20% of the
00:19African population,
00:20initially prioritizing those who are at the front line, the healthcare workers, then expanding to cover vulnerable groups such as
00:29the elderly or those with a pre-existing condition.
00:33I believe there are nine vaccines that have now entered the last stage of clinical testing, phase three clinical trials.
00:42Many more vaccines, probably over 35 at this point, have entered human clinical trials, and they are being tested in
00:51a number of settings globally.
00:53And it is important to test vaccines in different populations because there can be different responses among different populations.
Commenti